The latest price target for Exact Sciences (NASDAQ:EXAS) was reported by Barclays on January 23, 2025. The analyst firm set a price target for $70.00 expecting EXAS to rise to within 12 months (a possible 29.63% upside). 36 analyst firms have reported ratings in the last year.

The latest analyst rating for Exact Sciences (NASDAQ:EXAS) was provided by Barclays, and Exact Sciences initiated their overweight rating.

The last upgrade for Exact Sciences Corp happened on January 2, 2024 when Benchmark raised their price target to $91. Benchmark previously had a hold for Exact Sciences Corp.

The last downgrade for Exact Sciences Corp happened on August 2, 2023 when Benchmark changed their price target from N/A to N/A for Exact Sciences Corp.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Exact Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Exact Sciences was filed on January 23, 2025 so you should expect the next rating to be made available sometime around January 23, 2026.

While ratings are subjective and will change, the latest Exact Sciences (EXAS) rating was a initiated with a price target of $0.00 to $70.00. The current price Exact Sciences (EXAS) is trading at is $54.00, which is within the analyst’s predicted range.